Content about Prostate cancer

May 18, 2011

A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial.

WASHINGTON — A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial.

Data from the phase-2 study of the drug Rapaflo (silodosin) presented at the American Urological Association’s annual meeting showed that it reduced symptoms and improved outcomes in men with chronic prostatitis/pelvic pain syndrome, also known as CP/CPPS.

May 18, 2011

A cancer drug made by Amgen reduced the chances of prostate cancer spreading to the bones, according to results of a late-stage clinical trial presented at the American Urological Association’s annual meeting in Washington.

THOUSAND OAKS, Calif. — A cancer drug made by Amgen reduced the chances of prostate cancer spreading to the bones, according to results of a late-stage clinical trial presented at the American Urological Association’s annual meeting in Washington.

The phase-3 “Study ‘147” of Xgeva (denosumab) showed that men taking the drug survived for four months longer without the cancer spreading to their bones, compared with those taking placebo.

April 29, 2011

The Food and Drug Administration has approved a new treatment for prostate cancer made by Johnson & Johnson.

HORSHAM, Pa. — The Food and Drug Administration has approved a new treatment for prostate cancer made by Johnson & Johnson.

Centocor Ortho Biotech, J&J’s biotech subsidiary, announced Thursday the approval of Zytiga (abiraterone acetate), a daily pill for use in combination with the corticosteroid prednisone for treating castration-resistant prostate cancer that has spread to other parts of the body in men who have received prior chemotherapy with Sanofi-Aventis’ Taxotere (docetaxel).

March 24, 2011

GlaxoSmithKline withdrew all regulatory approval applications for a drug designed to cut men's risk of developing prostate cancer.

LONDON — GlaxoSmithKline withdrew all regulatory approval applications for a drug designed to cut men's risk of developing prostate cancer.

The drug maker announced it no longer would pursue global approval for Avodart (dutasteride) and would work with regulatory agencies to remove the indication from the product’s license.

March 11, 2011

The Food and Drug Administration has approved biotech company Dendreon’s expansion of manufacturing capacity for an immunotherapy treatment for prostate cancer, Dendreon said Thursday.

SEATTLE — The Food and Drug Administration has approved biotech company Dendreon’s expansion of manufacturing capacity for an immunotherapy treatment for prostate cancer, Dendreon said Thursday.

The company said it would be able to increase the ability of Provenge (sipuleucel-T) manufactured at its plant in New Jersey by increasing the number of workstations to produce it from 12 to 48.

The treatment is designed to induce an immune response against prostatic acid phosphatase, an antigen present in most prostate cancers.

March 11, 2011

While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.

TARRYTOWN, N.Y. — While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.

Sanofi and Regeneron announced Thursday results of the phase-3 “VITAL” trial of aflibercept. Patients were administered either the drug or placebo in addition to docetaxel chemotherapy.

January 27, 2011

The Food and Drug Administration declined to approve a regulatory approval application from British drug maker GlaxoSmithKline concerning a cancer drug, GSK said Wednesday.

LONDON — The Food and Drug Administration declined to approve a regulatory approval application from British drug maker GlaxoSmithKline concerning a cancer drug, GSK said Wednesday.

GSK said the FDA issued a complete response letter for its application seeking approval for Avodart (dutasteride) to reduce the risk of prostate cancer in men at increased risk of developing the disease. The drug already is approved to treat enlarged prostate.

October 19, 2010

Patients taking a certain class of drugs mostly used for prostate cancer may be at...

SILVER SPRING, Md. Patients taking a certain class of drugs mostly used for prostate cancer may be at higher risk of heart disease and diabetes, the Food and Drug Administration warned on Wednesday.

 

October 3, 2010

Safeway kicked off its annual breast cancer awareness initiative for the 10th year in a...

September 30, 2010

Data published in the latest issue of medical journal The Lancet showed that a recently...

BRIDGEWATER, N.J. Data published in the latest issue of medical journal The Lancet showed that a recently approved drug reduced the risk of death in men with a certain form of prostate cancer by more than a quarter.

 

September 29, 2010

Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals have started a late-stage clinical trial of an investigative...

BOTHELL, Wash. Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals have started a late-stage clinical trial of an investigative treatment for advanced prostate cancer, the two companies said Thursday.

 

Teva and OncoGenex, a company based in the Seattle suburb of Bothell, Wash., that develops cancer therapies, announced the start of “SYNERGY,” a phase-3 trial of OGX-011/TV-1011 (custirsen), a first-line therapy for treating castrate-resistant prostate cancer.

 

 

September 28, 2010

The Federal Trade Commission has sued the maker of a pomegranate juice that touts health...

WASHINGTON The Federal Trade Commission has sued the maker of a pomegranate juice that touts health benefit claims.

 

September 27, 2010

Pfizer has halted a late-stage trial of a drug therapy in men with prostate cancer,...

NEW YORK Pfizer has halted a late-stage trial of a drug therapy in men with prostate cancer, the drug maker said.

Pfizer announced the discontinuation of “SUN 1120,” a phase-3 trial of Sutent (sunitinib malate) combined with the generic drug prednisone in men with advanced castration-resistant prostate cancer that had progressed despite chemotherapy. An analysis of data from the trial found that the men were not more likely to improve overall survival when taking the two drugs together than when they took prednisone alone.

 

July 20, 2010

During what has become a familiar summer tradition that reaches millions of Safeway customers each...

June 16, 2010

The Food and Drug Administration has approved a new treatment for advanced prostate cancer, the...

June 13, 2010

Women with Type 2 diabetes may be more likely to develop certain cancers, a new...

June 2, 2010

The maker of Depend products is kicking off its “The Depend Campaign to End Prostate...

May 31, 2010

Safeway on Tuesday kicked off its annual prostate cancer fundraising and awareness campaign....

May 18, 2010

Amgen has submitted a regulatory approval application to the Food and Drug Administration for a...

May 2, 2010

Drug maker BioSante Pharmaceuticals has restarted a development program for a prostate cancer vaccine, the...

May 2, 2010

The Food and Drug Administration is investigating a possible link between drugs commonly used to...

March 30, 2010

Data from a long-term clinical trial may indicate a possible cancer risk in men taking...

March 11, 2010

A late-stage clinical trial of a Genentech drug for men with late-stage prostate cancer has...

March 1, 2010

The Food and Drug Administration has approved the first generic version of a drug for...

February 8, 2010

An investigational drug made by Amgen for treating prostate cancer that had spread to the...